Menu
Led by the National Collaborative Research Infrastructure Strategy (NCRIS) Therapeutic Innovation Australia (TIA), QDDA unites three flagship Queensland facilities: Compounds Australia, the Queensland Emory Drug Discovery Initiative (QEDDI), and the Centre for Integrated Preclinical Drug Development (CIPDD). This Queensland-led strategic alliance aims to enhance sector cohesion by strengthening and expanding a framework that enables academic and industry groups to advance drug discovery programs through key early stages of development. The goal is to grow Queensland’s pipeline of attractive, investor-ready small molecule therapeutic assets.
Compounds Australia provides compound libraries and compound management services to Queensland and Australian researchers. Based around a custom-designed suite of advanced robotics and high-density compound storage, Compounds Australia accelerates drug discovery by facilitating access to screening libraries and providing those libraries in customised assay-ready microplates ready for screening.
QEDDI, a business unit of UniQuest, the commercialisation company for the University of Queensland, specialises in translating academic biomedical research into drug candidates for partnering. QEDDI provides expert services in target validation, assay development, synthetic, medicinal, and computational chemistry, pharmacokinetics, drug pharmacology, and safety assessments, creating investment-ready lead molecules and comprehensive data packages aligned with industry and regulatory standards.
CIPDD provides advanced preclinical disease models and services for drug discovery-translation, enabling researchers to develop novel disease models, explore human pathobiology, and screen new compounds for in-vivo therapeutic efficacy, under a robust Quality Management System that meets international regulatory requirements.
© 2023 Therapeutic Innovation Australia Ltd. Design by Juno Creative.
